This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cantón, E.
Right arrow Articles by Serrano, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cantón, E.
Right arrow Articles by Serrano, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2005, p. 1604-1607, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1604-1607.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Sensititre YeastOne Caspofungin Susceptibility Testing of Candida Clinical Isolates: Correlation with Results of NCCLS M27-A2 Multicenter Study

Emilia Cantón,1* Javier Pemán,2 Miguel Gobernado,2 Elena Álvarez,3 Fernando Baquero,3 Ramón Cisterna,4 Joaquina Gil,5 Estrella Martín-Mazuelos,6 Carmen Rubio,5 Aurora Sánchez-Sousa,3 and Carmen Serrano6

Unidad de Microbiología Experimental-Centro de Investigación,1 Servicio de Microbiología, Hospital Universitario La Fe, Valencia,2 Hospital Universitario Ramón y Cajal, Madrid,3 Hospital Universitario Basurto, Bilbao,4 Hospital Clínico Universitario Lozano Blesa, Zaragoza,5 Hospital Universitario de Valme, Seville, Spain6

Received 21 October 2004/ Returned for modification 24 October 2004/ Accepted 27 November 2004

The ability of Sensititre YeastOne to discriminate isolates with reduced caspofungin susceptibility was determined against 36 Candida spp. (6 with a known FKS1 mutation). Results were compared with those of M27-A2. The MIC endpoint was 100% growth inhibition. Overall agreement (±2 log2) was 87.16%. Sensititre YeastOne detected strains with reduced caspofungin susceptibility.

* Corresponding author. Mailing address: Unidad de Microbiología Experimental, Centro de Investigación, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain. Phone: 34 96 1973111. Fax: 34 96 1973018. E-mail: canton_emi{at}gva.es.

Antimicrobial Agents and Chemotherapy, April 2005, p. 1604-1607, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1604-1607.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hakki, M., Staab, J. F., Marr, K. A. (2006). Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy.. Antimicrob. Agents Chemother. 50: 2522-2524 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»